Showing results (21-30 of 5,262) with videos related to

Sort By:
Pageof 527
European Journal of Haematology|December 24, 2010
Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish manAlejandro Del-Castillo-Rueda, María-Isabel Moreno-Carralero, Luis-Antonio Alvarez-Sala-Walther, et al.
European Journal of Haematology|December 21, 2010
GPI-anchored protein-deficient T cells in patients with aplastic anemia and low-risk myelodysplastic syndrome: implications for the immunopathophysiology of bone marrow failureTakamasa Katagiri, Zhirong Qi, Shigeki Ohtake, et al.
European Journal of Haematology|February 24, 2011
Physiological inhibitors of Wnt signalingAlexandra Filipovich, Iris Gehrke, Simon J Poll-Wolbeck, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
European Journal of Haematology|May 25, 2010
Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugsFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
European Journal of Haematology|May 25, 2010
Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective studyDongmei Ji, Junning Cao, Xiaonan Hong, et al.
European Journal of Haematology|June 10, 2010
Maternal serum hepcidin is low at term and independent of cord blood iron statusMari Rehu, Kari Punnonen, Vaughn Ostland, et al.
European Journal of Haematology|June 10, 2010
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab eraJuan-Manuel Sancho, Alberto Orfao, Sandra Quijano, et al.
European Journal of Haematology|September 30, 2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyMeletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, et al.
European Journal of Haematology|June 22, 2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek UnitVassilios Ladis, Giorgos Chouliaras, Vasilios Berdoukas, et al.
Pageof 527